Should You Buy the HMMJ ETF Right Now?

Investing in the Horizons Marijuana Life Sciences ETF (TSX:HMMJ) should help create massive wealth in the long-term.

| More on:
Modern skyscrapers in business district

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

In the last 15 months, cannabis stocks have time and again disappointed investors. Several stocks have lost close to 70% in market value in the last year. With structural issues grappling the marijuana sector, does it make sense to invest in the Horizon Marijuana Life Sciences ETF (TSX:HMMJ)?

This ETF provides investors with exposure to a basket of publicly listed pot stocks in North America. Though the HMMJ has grossly underperformed major North American indexes such as the Dow Jones Industrial Average and the S&P 500, the rapidly expanding addressable market in the cannabis space is too attractive for growth investors.

HMMJ Chart

HMMJ data by YCharts

Investing in an ETF provides diversification and reduces risk substantially. The HMMJ thus seems a winning bet for risk-oriented pot investors.

GW Pharmaceuticals is the top holding of the HMMJ

U.S.-based GW Pharmaceuticals (NASDAQ:GWPH) is the largest holding of the HMMJ and accounts for 14.1% of the ETF. This company has the only cannabis-based drug (epidiolex) approved by the FDA. Epidiolex helps to treat people with Dravet syndrome. Last year, the European Commission also approved the drug which will secure the company’s top-line growth in the upcoming decade.

Analysts expect GW Pharma to grow sales by 68.6% to US$525 million in 2020 and 57.4% to US$826.4 million in 2021. In 2018, its sales stood at a measly $12.7 million. GW Pharma stock is trading at a premium. Its market cap stands at $47.3 billion and the price to forward sales ratio is an astonishing 90. While the company continues to post an adjusted loss, it is expected to turn profitable in 2021.

GW Pharma’s price to 2021 earnings multiple stands at 27. In the next five years, GW Pharma earnings are expected to grow at a massive rate of 614% annually.

Canopy Growth accounts for 13.8% of the ETF

Canopy Growth (TSX:WEED)(NYSE:CGC) is a Canada-based cannabis giant. It accounts for 13.8% of the HMMJ ETF. This stock is currently trading on the TSX at $27.1, which is 64% below its record highs. Canopy Growth is backed by beverage giant Constellation Brands that has close to 40% stake in the former.

Constellation Brands’ investment in Canopy Growth has meant the pot heavyweight has a cash balance of $1.6 billion at the end of its most recent quarter. In the fiscal third quarter of 2020, Canopy reported sales of $123.8 million, up 62% sequentially. Its net loss fell from $375 million in Q2 to $124 million in Q3.

Canopy’s leadership position in Canada coupled with the above-mentioned investment and the legalization of cannabis 2.0 products make it a strong pick for long-term investors.

These are just two top stocks part of the HMMJ ETF. The cannabis industry is still at a nascent stage. The long-term outlook remains attractive as several states south of the border look to legalize marijuana. There is a huge growth opportunity in Europe as well, especially in the medical cannabis segment.

There are multiple players in the cannabis space currently. Similar to the dot.com bubble, only a handful of pot companies might be successful while several might go bankrupt, making HMMJ a compelling bet in an uncertain environment.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool owns shares of and recommends Constellation Brands. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Should You Stay Away From HEXO Stock?

HEXO (TSX:HEXO)(NASDAQ:HEXO) stock is on a downward spiral, and there is little hope it is going to recover soon.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why Did Aurora Cannabis (TSX:ACB) Stock Plunge 75% in 2022?

A prominent cannabis stock has plunged by 75% in 2022, as the company’s losses continue to mount in the face…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Fire & Flower: A Small Pot Stock Poised for Strong Growth

Fire & Flower is a cannabis retailer well-positioned for growth thanks to its digital and delivery initiatives.

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Is Sinking This Week

Starting another round of capital raising has hurt investor sentiments, and the Canadian cannabis giant’s performance on the stock market…

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Canopy Growth (TSX:WEED) Stock Plunged 19% Last Week

Canopy Growth Corp. (TSX:WEED)(NASDAQ:CGC) stock has plunged after the release of its final fiscal 2022 results.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Tanked 45% Last Week

There's no respite for Aurora Cannabis investors!

Read more »

Money growing in soil , Business success concept.
Cannabis Stocks

TFSA Investors: This Undervalued Gem Could Turn $6,000 Into $25,000

Here's why TFSA investors can hold undervalued growth stocks such as Verano in their portfolios right now.

Read more »

TSX Today
Cannabis Stocks

TSX Today: What to Watch for in Stocks on Monday, May 30

TSX investors should keep a close eye on the latest manufacturing data from China today.

Read more »